INVEST IN ROBOLIGENT TODAY!
Solid route to market: commercial collaborations for robot supply have been established, with the first unit shipped.
Vetted by National Science Foundation: won a highly competitive $1.2M SBIR grant from NSF with eligibility for a $500K matching grant. Friends and family round completed with $500K invested.
Cutting-edge technology and proven product-market fit: proprietary mobile manipulator robots for rehabilitation and AI-enabled automation based on cutting-edge, force-control technology with 5 pending patents.
Roboligent (formerly known as LinkDyn Robotics) designs robots that perform manual tasks safely using proprietary, cutting-edge force-control technology for automation. The robots behave like humans, making it easier to translate manual tasks into robotic behaviors in a way that’s safe and easy to interact with.
The first commercial application is robotic rehabilitation, where our robots can solve unmet needs in the clinical field. The first unit was shipped to our commercial collaborator for customer tests and marketing/sales activities. With another mobile robot variant, we are developing an autonomous mobile pick-and-deliver solution with advanced AI integration for the logistics automation market.
The Problem
Many service industries that require demanding and repetitive work have long suffered from labor shortages and high turnover rates. Physical therapy centers and warehouses are looking for automated solutions to replace their repetitive tasks, but we believe industrial robots on the market are not safe for human interaction.
Tasks that require human vision, mobility and manipulation are quite challenging to existing robots. The current market of industrial robots provide limited compatibility with AI perception which can result in injury and task failure. Conventional robots use position/velocity-control technology that produces extremely rigid movement with virtually no compliance. This is problematic as most manual tasks require direct, physical interaction with objects and humans in an environment, and conventional robots cannot adapt to unplanned interaction. Even a small positional uncertainty can lead to task failure.
While roboticists have been developing new systems to improve performance for the past couple of decades, only a few laboratory-level systems have been introduced. In the commercial market, robots that operate purely based on force-control with practical sensitivity, payload, reach and reliability are rare.
The Solution
At Roboligent we have developed a new robot that is safe and reliable for automating processes that can interact with humans. We designed an autonomous mobile manipulator system from the ground up based on proprietary force-control technology and integrated it with advanced AI algorithms. The system is equipped with a hypersensitive force-control manipulator robot that sits atop an autonomous mobile robot. It can automate a wide range of manual tasks that require human manipulation, mobility, and intelligence.
We have built three systems: the force-control robot arm, the mobile manipulator Optimo Regen, and the Optimo Dex integrated with robot control software and AI perception/autonomous navigation with application-level software.
The force-control technology allows our robots to behave like humans and translate manual tasks into the robot’s coded behaviors. Impedance or compliance control schemes can be applied for manipulation or guidance tasks even while lifting a heavy object or supporting the body. This allows for precise motion, compliance, and interactive behaviors. The robot generates an array of creative movements resembling human responses and behaviors to enable new automation with unprecedented performance and safety.
gif
The robot arm is highly sensitive and smooth for fragile object manipulation but strong enough to lift heavy objects. The mobile base autonomously navigates to reach targeted locations avoiding obstacles and humans. It is designed for utmost safety to work alongside humans and to interact with continuous physical contact. It is agile and versatile covering a wide work range.
The Market
We believe that our robots can help accelerate the sustained growth of the warehouse and physical therapy industries by alleviating the problems of high turnover rates and high intensity labor. The need for professional service robotics is on the rise.
With the increasing adoption of mobile robots, autonomous mobile manipulators are the next big wave expected to hit the service automation market. While the global autonomous robot market size was around $30B in 2019 and expected to reach $220B by 2030, the market size for pick and place automation is expected to reach $11B by 2025.
The market for global rehabilitation robots are on the rise due to rising cases of brain disease and an increasing aging population. By 2026, the market is projected to reach $2.6B with a CAGR of 22.1%. The market segments include therapeutic robots, exoskeleton robots, and assistive robots. North America is expected to dominate the global rehabilitation robots market due to the increasing demand for stroke rehabilitation. Each year 795,000 people in the U.S. have a stroke.
Our Traction
We are developing strong relationships with key organizations. Currently, we have established a contract with a Singaporean company, Seimitsu Factory Automation in Singapore (SFAS), for supplying our mobile manipulator as a robotic rehabilitation device toward the Asian market. They will conduct activities for a pilot study, marketing, sales, and customer relations, while we supply the complete product. The first unit was shipped in mid-April, 2021 for pilot study and pre-sales marketing.
We have also provided our force-control actuators to a robotics lab at Purdue University.
Along with this crowdfunding campaign, Roboiligent will initiate marketing and sales activities to discover customers and potential partners.
We won the SBIR Program from National Science Foundation (NSF) Phase I and II with a total of $1.2M of grant (the combined winning chance for phase I and II was around 3% at the time of our application). Under the SBIR Phase II that we are currently on, we are eligible to apply for 50% of matching funds ($500,000 maximum) to this crowdfunding investment. In addition, so far over 20 friends and family members have invested the company with a total of around $500,000.
What We Do
The mobile manipulator robots are designed to automate a wide range of human manual tasks with or without the integration of AI perception depending on applications. The robots are developed and constructed completely by Roboligent and backed by cutting-edge technology with five pending patents.
Optimo Regen
The goal of the Optimo Regen robot is to automate the physical laboring of physical/occupational therapists. The robot consists of the force-control manipulator and a detachable arm/leg brace sitting on a mobile base via a lifting column. The robot was designed to provide repetitive rehabilitation exercises to patients with motor deficits or paralysis, automating the demanding laboring from therapists.
Optimo Dex
This robot is built mainly for pick-and-deliver automation and consists of a force-control manipulator and a versatile gripper sitting on an autonomous mobile robot via a lifting column. The robot is intended to move to designated locations to pick and transport objects. To navigate arbitrary indoor environments, the mobile base is equipped with multiple RGB-depth cameras and a Lidar whose sensor-fusion outputs are fed into a SLAM (simultaneous localization and mapping) and navigation algorithms. To perform grasping tasks, deep learning networks analyze the images from the head and end-effector RGBD cameras to recognize targeted objects, measure their three-dimensional location, and estimate optimal grasping locations and poses.
gif
Similarly, along with a high-level deep perception and machine learning, the behavioral-level intelligence such as sensing objects and compliantly adapting to surroundings make it possible human-like dexterous manipulation and dynamic interaction.
For Optimo Dex, the manipulator is connected with a force-controllable and wide stroke gripper that can change its fingers on the go, meaning it can handle objects with a wide scope of materials, shapes, and sizes. For Optimo Regen, cuffs that make a connection with the human limbs are attached to the manipulator via a quick-release mechanism.
The Business Model
Hardware sales
Roboligent sells the robot hardware to diverse robotic industries. Hardware includes force-control actuators, robot arms, mobile rehabilitation robots, and mobile picking robots. Companies are increasingly discovering new commercial opportunities that can be addressed by force-control or compliant robots. Our plan is to strategically partner with these companies to supply our robots, avoiding overlaps of target markets among these companies. While we supply our robots as a subsystem or a whole system, they modify the system as needed and proceed with customer discovery and sales. The collaboration with Seimitsu Factory Automation in Singapore is an example of this model, and we are in active talks with more companies at this moment for supplying our products.
Robot-as-a-Service (RaaS) Model
In the long term, Roboligent expects to launch a Robot-as-a-Service (RaaS) model with the mobile manipulator to which we are currently adding more functionality and intelligence. The first application with a RaaS model is robotic rehabilitation for the US and EU markets. The second application is pick-and-deliver automation for warehouses and factories.
With a tentative RaaS model, the monthly rate will range from the monthly salary of physical therapy assistants to those of warehouse laborers. During 5 years of expected life, we expect to be able to generate a margin of up to $200,000 per unit.
How We Are Different
There are several companies that produce mobile manipulator robots and try to solve automation problems such as picking-transporting-placing in factories and warehouses. However, we believe there are not many strong use cases for commercial applications yet. Most of them are equipped with industrial robots on mobile platforms, which rely on AI perception and a moving base. This introduces positional uncertainty with rigid manipulation motions that cannot absorb those uncertainties. Even with safety measures, the rigid nature of motion generates a significant impact when collided. Robots have to be meticulously programmed for motion in human-collaborating environments for safety, leading to reduced productivity speeds. In our opinion, existing robots are more suitable to applications for semi-structured environments with objects arranged in particular ways limiting their application to broader human-robot collaborative tasks.
Our mobile manipulator, on the other hand, can work closely with humans as the manipulator can be stopped and pushed at any time. Our robots can even be stopped by an egg, as seen in the test video. The hyper transparent compliance makes it easy to automate tasks with caution-free physical interaction including touching, brushing, interrupting, pushing, pulling, hammering, etc. As a result, the manipulator performs tasks that robots struggle with. Its dynamically interactive and compliant manipulation is paired with AI perception for picking automation, not just stationary picking on conveyor belts in a quasi 2D environment, but mobile picking in full 3D situations with high variability. This allows the human body to maintain continuous physical contact with free or guided movements with precise support or assistance force, opening new possibilities of human-robot collaboration.
Note for force control manipulator: There are some laboratory-level force control robots for light payloads. Our product is a general, collaborative commercial-grade manipulator based on pure force control whose kind rarely exists in the commercial market. Some collaborative robot arms equipped with force sensors have a force control mode, but they are not sensitive enough to generate manipulation motion purely based on force control. They mainly operate in position/velocity control mode and switch to a force control mode when necessary with slow and cautious movement. One of the key traits of full force-control is the compliant and dynamic behaviors “during active manipulation motions”. Another aspect is how sensitive they are. For example, our robot arm responds to the weight of one playing card.
The Vision
In the next five years, we plan to become one of the top players in the service robotics field. We believe that our force-control, compliant robot will set the industry standard for safe, effective robots with intelligent performance.
To achieve the goal, we’ll focus on ramping up Optimo Regen sales to the Asian market from 2021 to 2022 while we proceed with the FDA application for the US market. On the development side, we plan to complete a beta prototype for the autonomous picking functionality on Optime Dex and conduct a pilot test in actual warehouse environments to start customer development in the logistics industry.
OUR LEADERSHIP
We are a small team, but we’ve successfully created a compelling robotic system with a tight budget and secured initial customers without aggressive spending on marketing and sales activities. Now is the time to grow our team to pursue our goals of accelerating our production, sales, and business growth.
The management team members, Bongsu Kim, Ph.D. in robotics, and Seonhwa Shin (M.S. in statistics), have 25 years of cumulative professional experience in engineering and bio-industry. They have contributed to the development of a widely-known exoskeleton robot featured by multimedia and renowned journals, and contributed to marketing, project management, and large-scale survey research. Our advisors having extensive business experience with serial entrepreneurship add seasoned perspectives to the company management.
Why Invest
We believe Roboligent’s advanced robotic technology has great potential in human-robot interactive and AI-based automation areas where huge commercial demands exist but conventional robots struggle to solve. Our first product, Optimo Regen, the unique force-control robot, is on a solid commercial route with our collaborator to make rehabilitation clinics more efficient. We are not stopping there. With advanced AI integration, Roboligent is paving the way to the broader collaborative automation market. With your support, we expect that Roboligent will be able to significantly increase the chance of their commercial success and bring a positive impact to society.
gif
We envision a world where robots are part of daily life, as intelligent tools making the way we live and work better. Our team at Roboligent is working on advancing toward a new robotic automation era where robots will work alongside humans.
We know entrepreneurial endeavors rarely bear fruit without universal public acceptance. With your participation, we believe we can create an army of ambassadors and early adopters who can amplify our innovation ripple into a large commercial wave.
Invest in Roboligent and help shape the future with us!
gif
Roboligent designs new types of mobile manipulator robots to automate mundane, manual tasks in service areas, such as clinics and logistics. The robots are built from the ground up based on patent-pending, force-control technology, integrated with advanced AI perception, enabling them to perform tasks previously hard to automate with existing robots.
James DeBacker
ROBOTICS Engr.
Jovita Ezeokafor
SOFTWARE Engr.
Yi Herng Ong
MECHANICAL Engr.
Seonhwa shin
OPERATING OFFICER
Alessandro Biglioli
Advisor
Karen Smetana
Advisor
Maximum Number of Shares Offered subject to adjustment for bonus shares
Company | : | Roboligent, Inc. |
Corporate Address | : | 11740 Jollyville Rd, Ste 200, Austin, TX 78759 |
Offering Minimum | : | $10,000.00 |
Offering Maximum | : | $3,499,993.60 |
Minimum Investment Amount(per investor) | : | $320.00 |
Offering Type | : | Equity |
Security Name | : | Common Stock |
Minimum Number of Shares Offered | : | 3,125 |
Maximum Number of Shares Offered | : | 1,093,748 |
Price per Share | : | $3.20 |
Pre-Money Valuation | : | $28,882,476.80 |
Voting Rights of Securities Sold in this Offering
Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Investment Incentives and Bonuses*
Time-Based:
Friends and Family Early Birds
Invest within the first 48 hours and receive an additional 10% bonus shares
Super Early Bird Bonus
Invest within the first five days and receive an additional 7% bonus shares
Early Bird Bonus
Invest within the first 10 days and receive an additional 5% bonus shares
Amount-Based:
$1500+ Investment Tier
3% Bonus share
Invest $1,500 and receive 3% bonus shares on your investment
$5,000+ Investment Tier
5% Bonus share
Invest $5,000 and receive 5% bonus shares on your investment
$10,000+ Investment Tier
7% Bonus share
Invest $10,000 and receive 7% bonus shares on your investment
$20,000+ Investment Tier
10% Bonus share and call with CEO
Invest $20,000 and receive 10% bonus shares on your investment
1-on-1 online meeting with the CEO of the company, including presentation and Q&A session.
The 10% StartEngine Owners’ Bonus
Roboligent will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of stock at $3.20 per share, you will receive and own 110 shares for $320. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will only receive a single Bonus Shares bonus, which will be the highest bonus rate they are eligible for.
*All perks occur when the offering is completed.
11.29.21
Today is the last day to invest!
With your support and interest so far, we were able to run a successful campaign and raise capital that will help us launch our first robot in the market. We are planning to launch our Optimo Regen in North America in early 2022.
Please join us! We’ll continue to keep our investors updated with quarterly newsletters and future fundraising rounds as we grow.
All the best,
Roboligent team
11.23.21
We are excited to announce the commercial version of Optimo Regen, our rehabilitation robot, starting production in Q1, 2022!
We’ve taken invaluable feedback from physical therapists and potential customers to refine the Regen and prepare for commercial launch. We believe the new Regen significantly enhances the clinical efficacy and operational efficiency that rehabilitation centers are looking for, and we plan to accept orders in early 2022 while proceeding with FDA clearance.
Our campaign ends next Monday. Please join us as we bring this product to market!
All the best,
Bongsu Kim, CEO
10.19.21
The global rehabilitation demand is rising due to increasing cases of brain disease and the aging population. Higher intensity, longer duration, and more repetition in therapy are known to be critical for recovery, which conflicts with usual clinical operations. Rehabilitation centers are actively looking for automated solutions as resource shortages and pressure for time efficiency challenge them to meet the needs. Research says that the rehabilitation robots market is estimated to reach $9.45 billion by 2027 with 20.5% of CAGR.
09.22.21
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, Roboligent has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Roboligent be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
09.07.21
Some people worry that robots and computers take over jobs. It is true in certain circumstances. For example, computers have made numerous jobs obsolete in history. Truck drivers and taxi drivers don’t always feel good about autonomous cars.
However, our robot helps workers to achieve better patient outcomes as a smart tool.
Physical rehabilitation is equipment and tool-intensive process. We are adding smart equipment that provides, we believe, way more effective therapeutic exercises and quantified motor function assessments that were impossible before.
An example of a physical therapy facility
In many cases, therapists cannot sit through an hour physically helping one patient. They have to take care of several patients at a time if necessary and utilize a variety of tools and equipment to let patients do exercises on their own. Our robot is designed to repeat manual exercises by highly-trained therapists to replace simple tool-based exercises. Still, robots need to be operated by therapists based on their physical rehabilitation knowledge and clinical experience. Without a human, it's just a dumb machine.
So, it's not that the robot replaces the job. It only makes the job stronger and sustainable. The beauty lies in that the synergetic collaboration of humans and robots will make us achieve more!
Invest today to make it happen together.
All the best,
Bongsu Kim, CEO
09.01.21
We’re excited to announce that the Roboligent crowdfunding campaign on StartEngine has raised over $300K from more than 125 investors!
Thank you again for joining us to help bring our cutting-edge robots to the next-generation automation era!
Please spread the word to your friends and family to join us.
Sincerely
Roboligent team
08.23.21
[The following is an automated notice from the StartEngine team].
Hello!
As you might know, Roboligent has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Roboligent be on the lookout for an email that describes more about the disbursement process.
This campaign will continue to accept investments until its indicated closing date.
Thanks for funding the future.
-StartEngine
08.23.21
HERE Life Science, our collaborator, has launched a new website! HERE focuses on the medical device business especially with our robot, Optimo Regen.
Many Asian countries are confronting the hardships of aging societies. One of the main concerns is how to maintain the quality of healthy life of the aged population under clinical resource shortages. For example, many hospitals and clinics in Singapore are looking for new automation solutions to maximize the time usage of physical therapy sessions. We believe Optimo Regen will be a perfect solution to the problem and customers agree, as HERE already starts to engage with some leading hospitals and therapists.
Invest today and be part of the journey!
Sincerely,
Bongsu Kim, CEO
08.12.21
Your investment will potentially be a 1.5X impact to Roboligent! We are applying for a matching funding opportunity to the National Science Foundation as a part of the SBIR program. We won the highly competitive and prestigious NSF SBIR phase I ($225,000) and phase II ($957,139) grants that are awarded to deep-tech startups with promising commercial potentials, rigorously selected by a group of engineering professors and business experts.
To accelerate commercialization, NSF offers the SBIR phase II awardees an opportunity for Matching Funding (Phase IIB) to private investment including equity crowdfunding. The matching funding is 50% of private investment funds, which is up to $500,000. Therefore, your investment will be able to create a 150% impact on Roboligent!
Invest today!
All the best,
Bongsu Kim, CEO
07.29.21
Optimo is a serious industrial-grade robot but so safe and organic that even a child can play with it!
Labor shortages and skills gap drive the demand for mobile manipulation robots. A large amount of recent institutional investments have accelerated innovations in the robotics industry for safe and dexterous robotic technology. Yet, the majority of robotics companies still rely on conventional robotic technology with additional sensors and computer vision, while the inherent shortcomings of robots remain unchanged.
We believe this new type of robot that behaves in a fundamentally different way will be the next standard of many robotic automation applications. Robotic rehabilitation is our first target market since existing solutions cannot address the issues regarding lack of exercise time and the necessity of automation that therapists and patients are sorely needing resolved. Our collaborator and hospitals who are up to clinical trials are excited about this new technology.
Please join Roboligent today!
Sincerely
Roboligent team
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$1,500+ Investment Tier
Invest $1,500 and receive 3% bonus shares on your investment.
$5,000+ Investment Tier
Invest $5,000 and receive 5% bonus shares on your investment.
$10,000+ Investment Tier
Invest $10,000 and receive 7% bonus shares on your investment.
$20,000+ Investment Tier
Invest $20,000 and receive 10% bonus shares on your investment and a 1-on-1 online meeting with the CEO of the company, including presentation and Q&A session.
0/2500
Cancel anytime before 48 hours before a rolling close or the offering end date.
We want you to succeed and get the most out of your money by offering rewards and memberships!
Your info is your info. We take pride in keeping it that way!
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Important Message
IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.
www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.
Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.
Investment opportunities posted and accessible through the site are of three types:
1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.
Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.
Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.
California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.
StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.